Dr. Julie Xing is the Executive Board Chair of Mundipharma China, a leading global pharmaceutical company, where she oversees all of the company’s operations in China. She is also a member of the global board of AptarGroup (NYSE: ATR), a leader in drug delivery, consumer product dispensing, and active material science solutions, as well as a global board advisor of Lee Kum Kee Group, a globally renowned enterprise in condiments, sauces, and health products. Additionally, she has served for five years on the board of Mars Incorporated, one of the largest global manufacturers in confectionery, food, pet food, and pet health. Before joining Mundipharma, Dr. Xing was the Senior Vice President and President of Greater China at Envista Holdings Corporation (NYSE: NVST), a dental instrument specialist and spin-off of Danaher Corporation,(NASDAQ: DHR) where she also served on the Global Executive Committee. Earlier in her career, Dr. Xing held executive roles at Eli Lilly & Company (NYSE: LLY), where she spent nearly a decade. At Eli Lilly’s global headquarters, she was responsible for global market access and new product planning for the diabetes product portfolio. She led global commercial assessments and new product planning for Tirzepatide (brand names: Zepbound, Mounjaro), a major weight-loss and Type 2 diabetes drug, and had contributed significantly to the rapid growth of several innovative medicines worldwide. She also served as Vice President of the Oncology Business and as Vice President of Market Access, Key Accounts, and Government Affairs for Eli Lilly China. Dr. Xing has also held senior positions with prominent biotechnology firms, including Affymetrix Inc. (now part of Thermo Fisher Scientific, NASDAQ: TMO), where she served as Global Vice President and General Manager of Asia Pacific, and Illumina Inc. (NASDAQ: ILMN), where she was President of China. Dr. Xing is highly influential in the healthcare industry and is frequently invited to deliver keynote addresses at prestigious forums organized by institutions, such as Peking University, Tsinghua University, and the China Europe International Business School. Her insights are widely respected by policymakers and industry experts. She currently serves as a member of the Executive Committee of the RDPAC (Research and Development Pharmaceutical Association Committee) and has previously been a board member of AdvaMed China (the China branch of the Advanced Medical Technology Association). In 2024, she was honored by Fortune (China) as one of China’s “Most Powerful Women in Business” (MPW). Dr. Xing has a strong scientific background, having earned her Ph.D. in Biology from the Hong Kong University of Science and Technology. She later conducted nearly four years of postdoctoral research at Harvard University and Stanford University School of Medicine, publishing numerous scientific papers. Dr. Xing is also a prolific writer and career coach, with over 100 published articles on career development, management, personal growth, and women in leadership. Her book Winning the Workplace was published by Fudan University Press in 2021 and became a bestseller.